Novel Developments in Stem Cell Mobilization Focus on CXCR4
Recently, the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology resear
- PDF / 7,915,128 Bytes
- 493 Pages / 439.37 x 666.14 pts Page_size
- 73 Downloads / 175 Views
Stefan Fruehauf
●
W. Jens Zeller
●
Gary Calandra
Editors
Novel Developments in Stem Cell Mobilization Focus on CXCR4
Editors Stefan Fruehauf Center for Tumor Diagnostics and Therapy Paracelsus Klinik Osnabrueck, Germany [email protected]
W. Jens Zeller German Cancer Research Center Heidelberg, Germany [email protected]
Gary Calandra, MD, PhD Private Consultant, Cresco, PA, USA [email protected]
ISBN 978-1-4614-1959-4 e-ISBN 978-1-4614-1960-0 DOI 10.1007/978-1-4614-1960-0 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2011945168 © Springer Science+Business Media, LLC 2012 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Due diligence has been taken in preparing this book, and its advice and information are believed to be true and accurate at the date of going to press. Nevertheless, neither the authors nor the editors nor the publisher accept any legal responsibility for any errors or omissions that may be made. The authors, the editors, and the publisher make no warranty, express or implied, with respect to the material contained in this book and they disclaim all liability for direct or consequential damages resulting from application of the information herein. In view of ongoing research and constant flow of information relating to drug (or biologic agent) therapy and reactions and in view of changes in governmental regulations, the reader is urged to carefully check the product information and instruction material in the package insert for each drug or biologic agent for any change in indications, contraindications, dosage, warnings, and precautions. This is of particular importance in regard to infrequently used or new drugs or biologic agents. In every individual case, the responsibility for application of the information in this book lies with the user or the practitioner. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Preface
Systemic cancer treatment led to increasing survival rates and even cures in an impressive number of tumor types within the last five decades, especially in patients with high-growth-fraction tumors benefitted from this development. Autologous transplantation of bone marrow or peripheral blood hematopoietic stem and progenitor cells (PB HSC/HPC) following high-dose chemotherapy allowed an up to sixfold increa
Data Loading...
